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Agar dilution MIC was used to test the activity of RWJ 54428, a new cephalosporin
derivative, compared to imipenem, meropenem, ceftriaxone, piperacillin, piperacillin–
tazobactam, clindamycin and metronidazole against 363 anaerobes isolated from clinical
specimens. RWJ 54428 had low MICs against most b-lactamase-negative Gram-negative
rods, and all Gram-positive strains except Clostridium difﬁcile. Imipenem andmeropenem
had the lowest MICs (MIC50s of 0.125mg/L and MIC90s of 1.0mg/L). Piperacillin–
tazobactam, clindamycin and metronidazole were active against most strains, and
ceftriaxone was active mainly against b-lactamase-negative organisms.
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Anaerobes are established causes of serious human
infections, especially in debilitated hosts. Although
infections caused by members of the Bacteroides
fragilis group occur most commonly, infections
caused by other Gram-negative anaerobic rods,
as well as by Gram-positive cocci and rods, are
increasingly encountered [1–10]. The susceptibility
spectrum of clinically isolated anaerobes is chan-
ging. Although b-lactamase production, and con-
comitant resistance to b-lactams, is the rule in the B.
fragilis group, both phenomena are increasingly
encountered in non-B. fragilis group Bacteroides,
Prevotella,Porphyromonas andFusobacterium species.
b-Lactamase production has also been described in
Clostridium butyricum, C. ramosum and C. clostridio-
forme. Metronidazole resistance is the rule among
Gram-positive non-spore-forming rods other than
Eubacterium species, but has also been reported in
peptostreptococci, non-C. perfringens clostridia, and
members of the B. fragilis group. Additionally, clin-
damycin resistance is not unusual among anaerobic
Gram-negative rods.Metalloenzyme-mediated car-
bapenem resistance in anaerobes is very rare in the
USA at the current time [1–10].
RWJ 54428 (MC-02,479) is a novel cephalosporin
with excellent activity against Gram-positive
organisms [11–17]. In order to shed light on the
anti-anaerobic activity of this compound, we com-
pared the activity of RWJ 54428 with that of imi-
penem, meropenem, ceftriaxone (as an example
of a broad-spectrum cephalosporin susceptible to
anaerobe b-lactamases), piperacillin, piperacillin–
tazobactam, clindamycin and metronidazole
against 363 anaerobes isolated from clinical speci-
mens by agar dilution MIC.
All anaerobic strains were clinical isolates
(1997–99) identiﬁed by conventional methodology
[18] and kept frozen in double-strength skimmed
milk (Difco Laboratories, Detroit, MI, USA) at
70 8C until use. Prior to testing, strains were
subcultured twice on enriched Brucella blood agar
plates. Throughout the study, strains were tested
for purity by Gram stain and colonial morphology.
RWJ 54428 susceptibility powder was obtained
from Ortho McNeil Laboratories, Raritan, NJ,
USA, and powders of other compounds from their
respective manufacturers.
b-Lactamase testing was by the nitroceﬁn disk
method [1–6] (Ceﬁnase: BBL Microbiology Sys-
tems, Cockeysville, MD, USA). No attempt was
made to differentiate between the type and
amount of b-lactamase(s) produced by each
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enzyme-positive strain. Agar dilution susceptibil-
ity testing of all 363 strains was performed accord-
ing to the method recommended by the National
Committee for Clinical Laboratory Standards
(NCCLS) [19], using Brucella agar (Difco Labora-
tories) with 5% sterile deﬁbrinated sheep blood
and inocula of 1 105CFU/spot. Tazobactam was
combined with piperacillin at a ﬁxed concen-
tration of 4.0mg/L. Incubation of all MIC plates
was done in an anaerobic glove box (Coy Labora-
tory Products, Ann Arbor, MI, USA) in an atmo-
sphere of 80%N2, 10% H2, and 10% CO2. Standard
quality control strains were included with each
run. Breakpoints were those approved by the
NCCLS.
b-Lactamase was detected in 77 of 86 isolates
(89.5%) of the B. fragilis group, 55 of 80 isolates
(68.8%) of Prevotella/Porphyromonas, and ﬁve of 42
isolates (11.9%) of fusobacteria. All Gram-positive
strains were b-lactamase negative.
Results of agar dilution MIC testing are present-
ed in Table 1. Overall, imipenem and meropenem
had the lowest MICs (MIC50s 0.125mg/L, MIC90s
1.0mg/L). RWJ 54428 had MICs 4.0mg/L
against all Gram-positive b-lactamase-negative
strains except C. difﬁcile, and b-lactamase-negative
anaerobic Gram-negative rods, with the exception
of F. mortiferum.
CeftriaxoneMICs paralleled those of RWJ 54428,
with low MICs found only for b-lactamase-nega-
tive strains, while piperacillin–tazobactam yielded
low MICs against both b-lactamase-positive and -
negative strains. Clindamycin resistance occurred
in some B. fragilis group strains and clostridia,
Table 1 Agar dilution MICs (mg/L)
against all 363 strains Strain MIC range MIC50 MIC90
B. fragilis (31/31)a
RWJ 54428 4.0 to >64.0 16.0 32.0
Imipenem 0.06–2.0 0.125 2.0
Meropenem 0.125–4.0 0.125 2.0
Ceftriaxone 4.0 to >64.0 32.0 64.0
Piperacillin 2.0 to >128.0 16.0 32.0
Piperacillin–tazobactam 0.125–8.0 0.5 4.0
Clindamycin 0.5 to >32.0 2.0 >32.0
Metronidazole 0.5–4.0 1.0 2.0
Bacteroides thetaiotaomicron (19/16)
RWJ 54428 16.0–64.0 32.0 64.0
Imipenem 0.125–0.25 0.25 0.25
Meropenem 0.25–0.5 0.25 0.5
Ceftriaxone >64.0 to >64.0 >64.0 >64.0
Piperacillin 32.0–128.0 64.0 128.0
Piperacillin–tazobactam 1.0–16.0 8.0 16.0
Clindamycin 1.0–16.0 4.0 8.0
Metronidazole 0.5–2.0 1.0 2.0
Bacteroides ovatus (10/10)
RWJ 54428 16.0 to >64.0 16.0 >64.0
Imipenem 0.125–1.0 0.25 0.25
Meropenem 0.25–2.0 0.25 0.5
Ceftriaxone 32.0 to >64.0 >64.0 >64.0
Piperacillin 16.0 to >128.0 32.0 128.0
Piperacillin–tazobactam 2.0–8.0 4.0 8.0
Clindamycin 2.0 to >32.0 2.0 >32.0
Metronidazole 1.0–2.0 1.0 2.0
Bacteroides vulgatus (10/10)
RWJ 54428 2.0–16.0 8.0 16.0
Imipenem 0.06–0.5 0.25 0.5
Meropenem 0.125–0.25 0.25 0.25
Ceftriaxone 2.0–16.0 8.0 16.0
Piperacillin 4.0–32.0 16.0 16.0
Piperacillin–tazobactam 1.0–32.0 2.0 16.0
Clindamycin 0.03–0.5 0.125 0.5
Metronidazole 0.5–2.0 0.5 1.0
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Bacteroides distasonis (11/5)
RWJ 54428 2.0 to >64.0 8.0 >64.0
Imipenem 0.125–2.0 0.5 2.0
Meropenem 0.125–8.0 0.25 8.0
Ceftriaxone 0.25 to >64.0 8.0 >64.0
Piperacillin 4.0 to >128.0 8.0 >128.0
Piperacillin–tazobactam 1.0–8.0 4.0 8.0
Clindamycin 4.0 to >32.0 8.0 16.0




RWJ 54428 4.0–16.0 8.0
Imipenem 0.06–0.5 0.125
Meropenem 0.06–0.5 0.125







RWJ 54428 2.0 to >64.0 16.0 >64.0
Imipenem 0.06–2.0 0.25 0.5
Meropenem 0.06–8.0 0.25 0.5
Ceftriaxone 0.25 to >64.0 64.0 >64.0
Piperacillin 2.0 to >128.0 16.0 128.0
Piperacillin–tazobactam 0.125–32.0 4.0 8.0
Clindamycin 0.03 to >32.0 2.0 16.0
Metronidazole 0.5–4.0 1.0 2.0
Prevotella bivia (30/24)
RWJ 54428 0.5–64.0 8.0 32.0
Imipenem 0.016–0.125 0.06 0.06
Meropenem 0.06–0.5 0.06 0.125
Ceftriaxone 0.25 to >64.0 8.0 64.0
Piperacillin 1.0–128.0 8.0 64.0
Piperacillin–tazobactam 0.125–0.25 0.125 0.125
Clindamycin 0.016–0.06 0.03 0.06
Metronidazole 0.5–8.0 4.0 4.0
Prevotella corporis (10/3)
RWJ 54428 0.03–16.0 0.03 8.0
Imipenem 0.016–0.06 0.03 0.06
Meropenem 0.008–0.125 0.06 0.06
Ceftriaxone 0.125–32.0 0.125 16.0
Piperacillin 0.25–64.0 0.5 16.0
Piperacillin–tazobactam 0.125–0.25 0.125 0.125
Clindamycin 0.016–32.0 0.016 0.03
Metronidazole 0.125–1.0 0.5 1.0
Prevotella melaninogenica (10/9)
RWJ 54428 0.125–32.0 1.0 32.0
Imipenem 0.016–0.06 0.03 0.03
Meropenem 0.03–0.125 0.06 0.125
Ceftriaxone 0.125–64.0 1.0 32.0
Piperacillin 1.0–64.0 4.0 32.0
Piperacillin–tazobactam 0.125 to 0.125 0.125 0.125
Clindamycin 0.016 to 0.016 0.016 0.016
Metronidazole 0.5–1.0 0.5 1.0
Table 1 continued
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Table 1 continued
Strain MIC range MIC50 MIC90
Prevotella intermedia (10/6)
RWJ 54428 0.03–32.0 8.0 32.0
Imipenem 0.016–0.06 0.03 0.06
Meropenem 0.03–0.06 0.06 0.06
Ceftriaxone 0.125–32.0 2.0 8.0
Piperacillin 0.25–32.0 8.0 32.0
Piperacillin–tazobactam 0.125 to 0.125 0.125 0.125
Clindamycin 0.016 to 0.016 0.016 0.016
Metronidazole 0.25–1.0 0.5 1.0
Miscellaneous strainsc (20/13)
RWJ 54428 0.008 to >64.0 8.0 >64.0
Imipenem 0.016–0.125 0.06 0.125
Meropenem 0.008–0.25 0.125 0.25
Ceftriaxone 0.125–64.0 1.0 64.0
Piperacillin 0.125–128.0 4.0 128.0
Piperacillin–tazobactam 0.125 to 0.125 0.125 0.125
Clindamycin 0.016–0.03 0.016 0.03
Metronidazole 0.125–4.0 2.0 4.0
Prevotella/Porphyromonas (80/55)
RWJ 54428 0.008 to >64.0 8.0 64.0
Imipenem 0.016–0.125 0.03 0.125
Meropenem 0.008–0.5 0.06 0.125
Ceftriaxone 0.125 to >64.0 4.0 64.0
Piperacillin 0.125–128.0 8.0 64.0
Piperacillin–tazobactam 0.125–0.25 0.125 0.125
Clindamycin 0.016–32.0 0.016 0.03
Metronidazole 0.125–8.0 2.0 4.0
Fusobacterium necrophorum (10/0)
RWJ 54428 0.008–0.06 0.008 0.03
Imipenem 0.016–0.03 0.016 0.016
Meropenem 0.008–0.016 0.008 0.016
Ceftriaxone 0.125 to 0.125 0.125 0.125
Piperacillin 0.125 to 0.125 0.125 0.125
Piperacillin–tazobactam 0.125 to 0.125 0.125 0.125
Clindamycin 0.03–0.06 0.06 0.06
Metronidazole 0.125–1.0 0.25 0.5
Fusobacterium nucleatum (10/1)
RWJ 54428 0.002–1.0 0.5 1.0
Imipenem 0.016–0.25 0.03 0.06
Meropenem 0.008–1.0 0.25 1.0
Ceftriaxone 0.125–4.0 1.0 2.0
Piperacillin 0.125 to >128.0 0.125 0.25
Piperacillin–tazobactam 0.125 to 0.125 0.125 0.125
Clindamycin 0.03–0.125 0.06 0.125
Metronidazole 0.125–0.5 0.125 0.25
Fusobacterium mortiferum (10/2)
RWJ 54428 1.0 to >64.0 >64.0 >64.0
Imipenem 0.25–1.0 0.5 1.0
Meropenem 0.06–0.5 0.25 0.5
Ceftriaxone 32.0 to >64.0 >64.0 >64.0
Piperacillin 0.25 to >128.0 1.0 >128.0
Piperacillin–tazobactam 0.25–1.0 0.5 1.0
Clindamycin 0.06–0.125 0.125 0.125
Metronidazole 0.125–0.5 0.125 0.5
Fusobacterium varium (12/2)
RWJ 54428 1.0–4.0 2.0 4.0
Imipenem 0.5–2.0 1.0 1.0
Meropenem 0.06–0.125 0.125 0.125
Ceftriaxone 0.125–8.0 4.0 8.0
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Piperacillin 2.0–64.0 8.0 32.0
Piperacillin–tazobactam 1.0–16.0 4.0 8.0
Clindamycin 1.0–32.0 4.0 32.0
Metronidazole 0.125–0.5 0.5 0.5
Fusobacteria (42/5)
RWJ 54428 0.002 to >64.0 1.0 >64.0
Imipenem 0.016–2.0 0.25 1.0
Meropenem 0.008–1.0 0.125 1.0
Ceftriaxone 0.125 to >64.0 2.0 >64.0
Piperacillin 0.125 to >128.0 0.25 32.0
Piperacillin–tazobactam 0.125–16.0 0.25 8.0
Clindamycin 0.03–32.0 0.06 16.0
Metronidazole 0.125–1.0 0.25 0.5
Peptostreptococcid (49/0)
RWJ 54428 0.004 to >64.0 0.06 2.0
Imipenem 0.016–2.0 0.03 0.5
Meropenem 0.008–4.0 0.06 0.5
Ceftriaxone 0.125–32.0 0.5 16.0
Piperacillin 0.125–32.0 0.25 2.0
Piperacillin–tazobactam 0.125–16.0 0.125 2.0
Clindamycin 0.03 to >32.0 0.5 4.0
Metronidazole 0.125 to >16.0 1.0 2.0
Propionibacterium spp. (17/0)
RWJ 54428 0.03–0.25 0.125 0.25
Imipenem 0.016–0.25 0.03 0.03
Meropenem 0.03–0.5 0.25 0.5
Ceftriaxone 0.25–1.0 0.25 0.5
Piperacillin 0.5–2.0 1.0 2.0
Piperacillin–tazobactam 0.25–2.0 1.0 1.0
Clindamycin 0.06–2.0 0.125 0.125
Metronidazole 1.0 to >16.0 >16.0 >16.0
Eubacterium spp. (12/0)
RWJ 54428 0.06–8.0 4.0 4.0
Imipenem 0.016–1.0 0.5 0.5
Meropenem 0.06–0.5 0.25 0.5
Ceftriaxone 0.25 to >64.0 64.0 >64.0
Piperacillin 0.25–64.0 16.0 32.0
Piperacillin–tazobactam 0.125–64.0 16.0 32.0
Clindamycin 0.03–2.0 0.25 2.0
Metronidazole 0.25–1.0 0.5 1.0
Lactobacillus spp. (11/0)
RWJ 54428 0.06–4.0 1.0 4.0
Imipenem 0.03–4.0 2.0 4.0
Meropenem 0.03 to >8.0 8.0 >8.0
Ceftriaxone 1.0 to >64.0 64.0 >64.0
Piperacillin 1.0–8.0 2.0 4.0
Piperacillin–tazobactam 1.0–4.0 2.0 4.0
Clindamycin 0.03–4.0 0.5 2.0




RWJ 54428 0.016–4.0 0.06 0.5
Imipenem 0.03–0.5 0.125 0.5
Meropenem 0.06–1.0 0.125 1.0
Ceftriaxone 0.125–8.0 1.0 2.0
Piperacillin 0.25–4.0 0.5 2.0
Table 1 continued
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while most anaerobic Gram-positive non-spore-
forming rods (with the exception of eubacteria)
and a few peptostreptococci were resistant to
metronidazole.
Results of MICs broken down by b-lactamase-
positive and -negative strains are presented in
Table 2. As can be seen, RWJ 54428 gave lowMICs,
especially against enzyme-negative Prevotella–
Table 1 continued
Strain MIC range MIC50 MIC90
Piperacillin–tazobactam 0.125–2.0 0.5 1.0
Clindamycin 0.016–8.0 0.06 1.0
Metronidazole 2.0 to >16.0 >16.0 >16.0
Clostridium perfringens (22/0)
RWJ 54428 0.004–2.0 0.03 0.06
Imipenem 0.016–0.25 0.06 0.125
Meropenem 0.008–0.125 0.016 0.125
Ceftriaxone 0.25–16.0 2.0 8.0
Piperacillin 0.125–2.0 0.25 1.0
Piperacillin–tazobactam 0.125–1.0 0.25 0.5
Clindamycin 0.125 to >32.0 2.0 8.0
Metronidazole 0.5–2.0 1.0 2.0
Clostridium difficile (10/0)
RWJ 54428 4.0–16.0 8.0 16.0
Imipenem 2.0–4.0 2.0 4.0
Meropenem 2.0–4.0 2.0 4.0
Ceftriaxone 32.0 to >64.0 32.0 64.0
Piperacillin 8.0–32.0 16.0 32.0
Piperacillin–tazobactam 8.0–32.0 8.0 16.0
Clindamycin 2.0 to >32.0 4.0 >32.0
Metronidazole 0.25–0.5 0.25 0.25
Other clostridiaf (22/0)
RWJ 54428 0.004–32.0 0.5 2.0
Imipenem 0.06–2.0 0.25 1.0
Meropenem 0.03–2.0 0.25 1.0
Ceftriaxone 0.25 to >64.0 0.5 16.0
Piperacillin 0.25–16.0 1.0 4.0
Piperacillin–tazobactam 0.125–16.0 0.25 4.0
Clindamycin 0.06–16.0 2.0 8.0
Metronidazole 0.25–2.0 0.5 1.0
All strains (363/137)
RWJ 54428 0.002 to >64.0 2.0 64.0
Imipenem 0.016–4.0 0.125 1.0
Meropenem 0.008 to >8.0 0.125 1.0
Ceftriaxone 0.125 to >64.0 8.0 >64.0
Piperacillin 0.125 to >128.0 4.0 >64.0
Piperacillin–tazobactam 0.125–64.0 0.25 8.0
Clindamycin 0.016 to >32.0 0.25 8.0
Metronidazole 0.125 to >16.0 1.0 8.0
aNo. of strains tested/no. of strains b-lactamase-positive.
bBacteroides merdae (1); Bacteroides caccae (1); Bacteroides splanchnicus (2); Bacteroides
stercoris (1).
cPrevotella oris (1); Prevotella denticola (1); Prevotella disiens (8); Prevotella buccae (8);
Porphyromonas asaccharolytica (2).
dPeptostreptococcus asaccharolyticus (8); Peptostreptococcus magnus (15); Peptostrep-
tococcus anaerobius (10); Peptostreptococcus micros (4); Peptostreptococcus prevotii (1);
Peptostreptococcus tetradius (11).
eActinomyces spp. (8); Bifidobacterium spp. (4).
fClostridium tertium (1); Clostridium bifermentans (2); Clostridium sordellii (6);
Clostridium cadaveris (1); Clostridium barattii (1); Clostridium hastiforme (1);
Clostridium innocuum (3); Clostridium ramosum (3); Clostridium paraputrificum (1);
Clostridium spp. (3).
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Porphyromonas, and Gram-positive anaerobes
other than C. difﬁcile, compared to b-lactamase-
positive strains.
RWJ 54428 is a novel parenteral cephalosporin
with excellent activity against Gram-positive aero-
bic organisms, including penicillin-susceptible
and -resistant pneumococci, ampicillin-suscepti-
ble Enterococcus faecalis and E. faecium, methicil-
lin-susceptible and -resistant staphylococci, and
vancomycin-intermediate Staphylococcus aureus.
Table 2 Comparison of MICs (mg/L) for b-lactamase-positive and -negative strains
b-lactamase negative b-lactamase positive
Organisms Range MIC50 MIC90 Range MIC50 MIC90
B. fragilis
group (9/77)a
RWJ 54428 2.0–64.0 8.0 2.0 to >64.0 16.0 >64.0
Imipenem 0.25–2.0 0.5 0.06–2.0 0.25 0.5
Meropenem 0.125–8.0 0.25 0.06–4.0 0.25 0.5
Ceftriaxone 0.25 to >64.0 4.0 2.0 to >64.0 64.0 >64.0
Piperacillin 4.0–64.0 8.0 2.0 to >128.0 16.0 128.0
Piperacillin–tazobactam 1.0–16.0 4.0 0.125–32.0 2.0 8.0
Clindamycin 2.0–16.0 8.0 0.03 to >32.0 2.0 >32.0
Metronidazole 1.0–2.0 1.0 0.5–4.0 1.0 2.0
Prevotella/Porphyromonas (25/55)
RWJ 54428 0.008–2.0 0.06 1.0 0.125 to >64.0 16.0 64.0
Imipenem 0.016–0.06 0.03 0.06 0.016–0.125 0.06 0.125
Meropenem 0.008–0.125 0.06 0.06 0.03–0.5 0.06 0.125
Ceftriaxone 0.125–1.0 0.125 0.5 0.125 to >64.0 8.0 64.0
Piperacillin 0.125–4.0 0.5 4.0 1.0–128.0 16.0 128.0
Piperacillin–tazobactam 0.125–0.125 0.125 0.125 0.125–0.25 0.125 0.125
Clindamycin 0.016–0.03 0.016 0.03 0.016–32.0 0.016 0.06
Metronidazole 0.125–4.0 1.0 4.0 0.125–8.0 2.0 4.0
Fusobacteria (37/5)
RWJ 54428 0.02 to >64.0 1.0 >64.0 1.0 to >64.0 2.0
Imipenem 0.016–1.0 0.25 1.0 0.06–2.0 0.5
Meropenem 0.008–1.0 0.125 1.0 0.06–0.5 0.125
Ceftriaxone 0.125 to >64.0 2.0 >64.0 0.125 to >64.0 4.0
Piperacillin 0.125–64.0 0.25 8.0 2.0 to >128.0 >128.0
Piperacillin–tazobactam 0.125–16.0 0.125 4.0 0.125–8.0 1.0
Clindamycin 0.03–32.0 0.06 16.0 0.06–16.0 0.125
Metronidazole 0.125–1.0 0.25 0.5 0.125–0.5 0.25
Gram-positive strainsb (145/0)
RWJ 54428 0.004 to >64.0 0.125 4.0
Imipenem 0.016–4.0 0.06 1.0
Meropenem 0.008 to >8.0 0.125 1.0
Ceftriaxone 0.125 to >64.0 1.0 64.0
Piperacillin 0.125–64.0 0.5 8.0
Piperacillin–tazobactam 0.125–64.0 0.25 4.0
Clindamycin 0.016 to >32.0 0.5 8.0
Metronidazole 0.125 to >16.0 1.0 >16.0
All strainsb (216/137)
RWJ 54428 0.002 to >64.0 0.125 4.0 0.125 to >64.0 16.0 >64.0
Imipenem 0.016–4.0 0.06 1.0 0.016–2.0 0.125 0.5
Meropenem 0.008 to >8.0 0.06 1.0 0.03–4.0 0.125 0.5
Ceftriaxone 0.125 to >64.0 0.5 64.0 0.125 to >64.0 32.0 >64.0
Piperacillin 0.125–64.0 0.5 8.0 1.0 to >128.0 16.0 128.0
Piperacillin–tazobactam 0.125–64.0 0.125 4.0 0.125–32.0 0.25 8.0
Clindamycin 0.016 to >32.0 0.25 8.0 0.016 to >32.0 0.5 8.0
Metronidazole 0.125 to >16.0 1.0 >16.0 0.125–8.0 1.0 4.0
aNumber b-lactamase negative/number b-lactamase positive.
bExcept for C. difficile.
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The compound shows bactericidal activity at and
above the MIC, and a signiﬁcant postantibiotic
effect against multiresistant Gram-positive bacte-
ria. Its potent antistaphylococcal activity is related
to penicillin-binding protein 2a. Minimal inocu-
lum effects are found by agar dilution [11–17].
MICs of other compounds tested are similar to
those described previously. Clindamycin resis-
tance in B. fragilis group organisms and metroni-
dazole resistance in peptostreptococci has been
reported before [1–9].
Results of the current study show that RWJ
54428 had low MICs only against b-lactamase-
negative anaerobic strains. If this compound is
to have additional activity against b-lactamase-
positive organisms, combination with a b-lacta-
mase inhibitor will be necessary. Further in vitro
and other experimental studies will be necessary
in order to test this hypothesis.
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